General Information of DTT (ID: TT9HKJA)

DTT Name Vascular endothelial growth factor (VEGF) DTT Info
Gene Name VEGF

Molecule-Related Drug & Molecule List

Molecule-Related Drug List
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
1 Approved Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brolucizumab DMW8QNG Wet age-related macular degeneration 9B78.3Z Approved [1]
------------------------------------------------------------------------------------
19 Clinical Trial Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
FKB238 DM6R2XF Non-small-cell lung cancer 2C25.Y Phase 3 [2]
KSI-301 DMM2LTC Diabetic macular edema 9B71.02 Phase 3 [3]
M710 DM1PRT6 Diabetic macular edema 9B71.02 Phase 3 [4]
MYL-1402O DMXN2PP Non-small-cell lung cancer 2C25 Phase 3 [5]
PF-06439535 DMVHZDP Non-small-cell lung cancer 2C25.Y Phase 3 [6]
SB15 DMTOS6C Neovascular age-related macular degeneration 9B78.3Z Phase 3 [7]
Squalamine DM3PS2E Solid tumour/cancer 2A00-2F9Z Phase 3 [8]
TRS003 DMM1VOH Colorectal cancer 2B91.Z Phase 3 [9]
ALG-1001 DMR2YPF Diabetic macular edema 9B71.02 Phase 2 [10]
AVA-101 DMASRP3 Age-related macular degeneration 9B75.0 Phase 2 [11]
Dilpacimab DMCATH2 Solid tumour/cancer 2A00-2F9Z Phase 2 [12]
TG100801 DMPH1AG Macular degeneration 9B78.3 Phase 2 [13]
ABT-165 DMQ3O1U Solid tumour/cancer 2A00-2F9Z Phase 1 [14]
BI 836880 DMRI6YT Neoplasm 2A00-2F9Z Phase 1 [15]
BI-836880 DMGFH7T Solid tumour/cancer 2A00-2F9Z Phase 1 [16]
NM-3 DM5INE7 Solid tumour/cancer 2A00-2F9Z Phase 1 [17]
NOV1501 DME2QUZ Solid tumour/cancer 2A00-2F9Z Phase 1 [18]
PAN-90806 DMY9LG1 Diabetic retinopathy 9B71.0 Phase 1 [19]
Zifibancimig DMIJ2MZ Neovascular age-related macular degeneration 9B78.3Z Phase 1 [20]
------------------------------------------------------------------------------------
⏷ Show the Full List of 19 Clinical Trial Drug(s)
1 Investigative Drug(s) Transported by This DTP
Drug Name Drug ID Indication ICD 11 Highest Status REF
BIBF100 DMUWO6D Multiple myeloma 2A83 Investigative [21]
------------------------------------------------------------------------------------
Molecule Interaction Atlas

References

1 Brolucizumab: First Approval. Drugs. 2019 Dec;79(18):1997-2000.
2 Clinical pipeline report, company report or official report of Fujifilm.
3 Clinical pipeline report, company report or official report of Kodiak Sciences.
4 ClinicalTrials.gov (NCT03610646) Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea in Subjects With Diabetic Macular Edema. U.S. National Institutes of Health.
5 MYL-1402O: A Bevacizumab Biosimilar. Target Oncol. 2022 Jan;17(1):85-88.
6 National Cancer Institute Drug Dictionary (drug id 43234).
7 Efficacy and Safety of the Aflibercept Biosimilar SB15 in Neovascular Age-Related Macular Degeneration: A Phase 3 Randomized Clinical Trial. JAMA Ophthalmol. 2023 Jul 1;141(7):668-676.
8 Clinical pipeline report, company report or official report of Ohr Pharmaceutical.
9 Prevalence of porcine cysticercosis in Vellore, South India. Trans R Soc Trop Med Hyg. 2013 Jan;107(1):62-4.
10 Future therapies of wet age-related macular degeneration. J Ophthalmol. 2015;2015:138070.
11 Clinical pipeline report, company report or official report of Avalanche Biotechnologies.
12 Apoptogenic activity of 2alpha,3alpha-dihydroxyurs-12-ene-28-oic acid from Prunella vulgaris var. lilacina is mediated via mitochondria-dependent activation of caspase cascade regulated by Bcl-2 in human acute leukemia Jurkat T cells. J Ethnopharmacol. 2011 Jun 1;135(3):626-35.
13 Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol. 2008 Jul;216(1):29-37.
14 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
15 Clinical pipeline report, company report or official report of Boehringer Ingelheim.
16 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
17 2-(8-hydroxy-6-methoxy-1-oxo-1h-2-benzopyran-3-yl) propionic acid, an inhibitor of angiogenesis, ameliorates renal alterations in obese type 2 diabetic mice. Diabetes. 2006 May;55(5):1232-42.
18 Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer. BMB Rep. 2020 Nov;53(10):533-538.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 Clinical pipeline report, company report or official report of Roche
21 Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127.